Six years ago, our UAB SPORE in Pancreatic Cancer application was partially funded via a P-20 grant. With limited funding;our mini-SPORE was composed of 2 major projects, 3 Cores and a Developmental Research Program. During this initial funding period, translation of SPORE science resulted in two phase I trials, one Phase II trial and a novel MRI imaging trial. The investigators of the SPORE have 88 publications relating to SPORE projects or pancreatic cancer. The Developmental Research funding resulted in two major projects, Projects 1, &4 in this renewal application and 2 awardees becoming Project co-leaders. Three years ago, Dr. Vickers (SPORE PI) became Chairman of Surgery at the University of Minnesota (UMN) and we restructured into a joint UAB/UMN SPORE in Pancreatic Cancer. The joint SPORE has functioned well and this proposal is our amended competitive renewal for full SPORE funding (PSO application). This proposal has 4 major projects: Project 1 is utilizing proteomic techniques in transgenic animal models to identify biomarkers that are predictive of early stage pancreatic cancer;Project 2 is a continuation project which is examining multiple methods to enhance the therapeutic efficacy of anti-DR5 monoclonal antibodies in pancreatic cancer animal models and patients;Project 3 is utilizing genomic and genetic data obtained from human pancreatic cancer (PCa) samples and observations from mouse models of PCa to understand the genetic events that drive metastasis and treatment resistance in this disease. These studies will lead to a phase I clinical trial;Project 4 is engineering novel conditionally replicative adenoviral vectors that target pancreatic cancer stem cell-like tumor cells for the treatment of metastatic pancreatic cancer. The four important and effective Cores are: 1) Administration;2) Tissue Resource and Molecular Pathology;3) Biostatistics;and 4) Clinical Management and Trials (Advocacy Sub-Core). We also request support for continuation of our Developmental Research and Career Development Programs which includes Morehouse School of Medicine and Tuskegee University. The application has strong institutional support from UAB and UMN, excellent pancreatic cancer populations and concurrence with federal guidelines.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA101955-06A2
Application #
7939097
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Program Officer
Agarwal, Rajeev K
Project Start
2003-09-16
Project End
2015-06-30
Budget Start
2010-08-18
Budget End
2011-06-30
Support Year
6
Fiscal Year
2010
Total Cost
$2,300,000
Indirect Cost
Name
University of Alabama Birmingham
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Tiriac, Hervé; Belleau, Pascal; Engle, Dannielle D et al. (2018) Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov 8:1112-1129
Tiriac, Herve; Bucobo, Juan Carlos; Tzimas, Demetrios et al. (2018) Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy sampling for personalized cancer treatment. Gastrointest Endosc 87:1474-1480
Carlson, Marjorie; Watson, Adrienne L; Anderson, Leah et al. (2017) Multiphoton fluorescence lifetime imaging of chemotherapy distribution in solid tumors. J Biomed Opt 22:1-9
Öhlund, Daniel; Handly-Santana, Abram; Biffi, Giulia et al. (2017) Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med 214:579-596
Zhong, Yi; Macgregor-Das, Anne; Saunders, Tyler et al. (2017) Mutant p53 Together with TGF? Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer. Clin Cancer Res 23:1607-1620
Contreras, Carlo M; Lin, Chee Paul; Oster, Robert A et al. (2017) Increased pancreatic cancer survival with greater lymph node retrieval in the National Cancer Data Base. Am J Surg 214:442-449
Roe, Jae-Seok; Hwang, Chang-Il; Somerville, Tim D D et al. (2017) Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Cell 170:875-888.e20
Chio, Iok In Christine; Tuveson, David A (2017) ROS in Cancer: The Burning Question. Trends Mol Med 23:411-429
Li, Yonghe; Oliver, Patsy G; Lu, Wenyan et al. (2017) SRI36160 is a specific inhibitor of Wnt/?-catenin signaling in human pancreatic and colorectal cancer cells. Cancer Lett 389:41-48
Feigin, Michael E; Garvin, Tyler; Bailey, Peter et al. (2017) Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Nat Genet 49:825-833

Showing the most recent 10 out of 173 publications